Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies. Its prioritized product candidate is oral levosimendan (TNX-103), currently in two Phase 3 clinical trials (LEVEL and LEVEL-2) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). The company has also deprioritized a Phase 3 trial of imatinib for pulmonary hypertension. Both drugs are already approved in other indications worldwide. Tenax has no approved products currently on the market.
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-10 | 2025-12-31 | 0001193125-26-099393 | EDGAR | 47K words |
| 2025-03-25 | 2024-12-31 | 0000950170-25-044398 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001654954-24-003827 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001654954-23-003945 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001654954-22-004036 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001654954-21-003641 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001654954-20-003498 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001654954-19-003861 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001654954-18-003517 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001654954-17-002098 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-31 | 2026-06-30 | 0001193125-26-327455 | EDGAR | — |
| 2025-11-12 | 2025-09-30 | 0001193125-25-277793 | EDGAR | 14K words |
| 2025-08-13 | 2025-06-30 | 0000950170-25-108063 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071395 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001654954-24-014262 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001654954-24-010456 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001654954-24-006228 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001654954-23-014168 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001654954-23-010758 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001654954-23-006566 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001654954-22-015030 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001654954-22-011073 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-10 | 0001193125-26-341236 | EDGAR | — |
| 2026-07-31 | 0001193125-26-326784 | EDGAR | — |
| 2026-03-10 | 0001654954-26-002072 | EDGAR | 1K words |
| 2026-01-09 | 0001654954-26-000232 | EDGAR | — |
| 2025-12-17 | 0001654954-25-014059 | EDGAR | — |
| 2025-11-12 | 0001654954-25-012921 | EDGAR | — |
| 2025-09-16 | 0001654954-25-010792 | EDGAR | — |
| 2025-09-09 | 0001654954-25-010510 | EDGAR | — |
| 2025-08-13 | 0001654954-25-009510 | EDGAR | — |
| 2025-06-17 | 0001654954-25-007104 | EDGAR | — |
385 total filings indexed. 353 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000034956 |
| Ticker | TENX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.tenaxthera.com |
| Listed | 1995-02-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TENX (~200 tokens, structured JSON with cryptographic provenance)